Arturo LoAIza-Bonilla, Systemwide Chief of Hematology and Oncology at St. Luke’s University Health Network, shared on LinkedIn:
“Hope in a bottle.
Laura was the first of now several patients with pancreatic cancer who are obtaining Daraxonrasib via the Expanded Access Program. Grateful of being able to provide this innovative program to our patients and communities across the Lehigh Valley and beyond.
And kudos to Beige Zinkler and Jen Castillo for all their help to make it happen!”
You can also read FDA Accepts Daraxonrasib NDA for Review in Previously Treated Metastatic Pancreatic Cancer on OncoDaily.
